Your browser doesn't support javascript.
Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial.
Wang, Jia-Bo; Wang, Zhong-Xia; Jing, Jing; Zhao, Peng; Dong, Jing-Hui; Zhou, Yong-Feng; Yang, Guang; Niu, Ming; Zhao, Xu; Jiang, Tian-Jun; Bi, Jing-Feng; Xu, Zhe; Zhang, Ping; Wu, Dan; Bai, Zhao-Fang; Guo, Yu-Ming; Yu, Si-Miao; Sun, Yong-Qiang; Zhang, Zi-Teng; Zhan, Xiao-Yan; Li, Peng-Yan; Ding, Jin-Biao; Zhao, Peng-Fei; Song, Xue-Ai; Tang, Jian-Yuan; He, Dong-Chu; Chen, Zhu; Qin, En-Qiang; Wang, Rui-Lin; Xiao, Xiao-He.
  • Wang JB; China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Wang ZX; Integrative Medical Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Jing J; Integrative Medical Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Zhao P; Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Dong JH; National Clinical Research Center for Infectious Diseases, Beijing, 100039, China.
  • Zhou YF; Department of Radiology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Yang G; China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Niu M; Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Zhao X; China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Jiang TJ; China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Bi JF; Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Xu Z; Research Center for Clinical and Translational Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Zhang P; Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Wu D; China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Bai ZF; Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Guo YM; China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Yu SM; China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Sun YQ; Integrative Medical Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Zhang ZT; Integrative Medical Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Zhan XY; China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Li PY; China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Ding JB; China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Zhao PF; Research Center for Clinical and Translational Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • Song XA; College of Life Science, Beijing University of Chinese Medicine, Beijing, 100029, China.
  • Tang JY; Integrative Medical Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
  • He DC; Sichuan Evidence-Based Medicine Center of Traditional Chinese Medicine Affliated Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
  • Chen Z; Department of Integrated Treatment, General Hospital of Central Theater Command, Wuhan, 430070, China.
  • Qin EQ; National Clinical Research Center for Infectious Diseases, Beijing, 100039, China.
  • Wang RL; Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China. qeq2004@sina.com.
  • Xiao XH; National Clinical Research Center for Infectious Diseases, Beijing, 100039, China. qeq2004@sina.com.
Chin J Integr Med ; 26(9): 648-655, 2020 Sep.
Article in English | MEDLINE | ID: covidwho-648556
ABSTRACT

OBJECTIVES:

To develop a new Chinese medicine (CM)-based drug and to evaluate its safety and effect for suppressing acute respiratory distress syndrome (ARDS) in COVID-19 patients.

METHODS:

A putative ARDS-suppressing drug Keguan-1 was first developed and then evaluated by a randomized, controlled two-arm trial. The two arms of the trial consist of a control therapy (alpha interferon inhalation, 50 µg twice daily; and lopinavir/ritonavir, 400 and 100 mg twice daily, respectively) and a testing therapy (control therapy plus Keguan-1 19.4 g twice daily) by random number table at 11 ratio with 24 cases each group. After 2-week treatment, adverse events, time to fever resolution, ARDS development, and lung injury on newly diagnosed COVID-19 patients were assessed.

RESULTS:

An analysis of the data from the first 30 participants showed that the control arm and the testing arm did not exhibit any significant differences in terms of adverse events. Based on this result, the study was expanded to include a total of 48 participants (24 cases each arm). The results show that compared with the control arm, the testing arm exhibited a significant improvement in time to fever resolution (P=0.035), and a significant reduction in the development of ARDS (P=0.048).

CONCLUSIONS:

Keguan-1-based integrative therapy was safe and superior to the standard therapy in suppressing the development of ARDS in COVID-19 patients. (Trial registration No. NCT04251871 at www.clinicaltrials.gov ).
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Drugs, Chinese Herbal / Interferon-alpha / Coronavirus Infections / Severe Acute Respiratory Syndrome / Lopinavir Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Traditional medicine Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Chin J Integr Med Journal subject: Complementary Therapies Year: 2020 Document Type: Article Affiliation country: S11655-020-3426-7

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Drugs, Chinese Herbal / Interferon-alpha / Coronavirus Infections / Severe Acute Respiratory Syndrome / Lopinavir Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Traditional medicine Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Chin J Integr Med Journal subject: Complementary Therapies Year: 2020 Document Type: Article Affiliation country: S11655-020-3426-7